Abstract:Background: Patients with ovarian cancer have high platelet counts, which correlate with disease burden, incidence, and lethality of blood clots (thrombosis). We hypothesized that elevated aggregation is associated with both increased platelet number and altered behavior of platelets in patients with ovarian cancer. Methods: Healthy controls and patients with suspected or diagnosed ovarian cancer were evaluated for complete blood counts. To evaluate the effects of platelet count versus platelet behavior, equal platelet-rich plasma (PRP) volumes versus equal platelet numbers were used in platelet aggregation assays. Arachidonic acid, adenosine diphosphate, and collagen platelet agonists were used to induce aggregation. Volunteers were grouped into healthy controls (23), benign/borderline cases (7), and cancer cases (25 ovarian, 1 colorectal, and 2 endometrial). Results: The rate and amount of platelet aggregation were higher in patients compared to healthy controls regardless of whether the same platelet number or PRP volume was used. Compared to healthy controls, patients with untreated ovarian cancer exhibited high levels of platelet activation markers, P-selectin (27.06 vs. 31.06 ng/mL, p = 0.03), and beta-thromboglobulin (3.073 vs. 4.091 μg/mL, p = 0.02) in their plasma. The significance of the elevation and its correlations with platelet number or PRP volume varied depending on the agonist. Platelet (305.88 vs. 134.12, p < 0.0001) and white blood cell (8.459 vs. 5.395, p < 0.01) counts (×109/L) were elevated pre-chemotherapy and decreased post-chemotherapy, respectively. Conclusions: Elevated platelet aggregation is caused by both altered platelet number and behavior in patients with ovarian cancer. These results support the study of antiplatelet agents for thrombosis prevention in these patients.

Platelets Increase the Expression of PD-L1 in Ovarian Cancer

Platelets Are Associated with Xenograft Tumor Growth and the Clinical Malignancy of Ovarian Cancer Through an Angiogenesis-Dependent Mechanism.

Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-β signaling pathway.

Activated platelets facilitate hematogenous metastasis of breast cancer by modulating the PDGFR-β/COX-2 axis

The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy

Platelet-activating Factor Acetyl Hydrolase IB2 Dysregulated Cell Proliferation in Ovarian Cancer

Differential platelet levels affect response to taxane-based therapy in ovarian cancer

Platelet RNA Enables Accurate Detection of Ovarian Cancer: an Intercontinental, Biomarker Identification Study.

In Situ Activation of Platelets with Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy

Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count

Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer

Implications of GPIIB-IIIA Integrin and Liver X Receptor in Platelet-Induced Compression of Ovarian Cancer Multi-Cellular Spheroids

Platelets Promote Breast Cancer Cell MCF-7 Metastasis by Direct Interaction: Surface Integrin Alpha 2 Beta 1-Contacting-mediated Activation of Wnt-beta-catenin Pathway

Inhibition of Platelet Function: Does It Offer a Chance of Better Cancer Progression Control?

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression

Engineering PD-1-Presenting Platelets for Cancer Immunotherapy.

PD-L1 Regulates Platelet Activation and Thrombosis via Caspase-3/GSDME Pathway

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer

Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance